Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 3, 2010, Pages 372-376

  Kim, Hee Seung ^a   Wainer, Irving W ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Capillary electrophoresis; Doxorubicin; Laser induced fluorescence; Liposomal doxorubicin; Stability

Indexed keywords

DOXORUBICIN;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STABILITY; ENCAPSULATION; FLUORESCENCE; FREEZE THAWING; HUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; BUFFERS; CALIBRATION; DOXORUBICIN; DRUG STABILITY; ELECTROPHORESIS, CAPILLARY; FLUORESCENCE; FREEZING; HUMANS; HYDROGEN-ION CONCENTRATION; LASERS; LIMIT OF DETECTION; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 77649181288     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.06.028     Document Type: Article

References (12)

1. Chabner B.A., Ryan D.R., Paz-Ares L., Garcia-Carbonero R., and Calabresi P. Antineoplastic agents. In: Hardman J.G., Limbird J.E., and Goodman A.G. (Eds). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. tenth edition (2001), McGraw-Hill, New York 1428
2. Tardi P.G., Boman N.L., and Cullis P.R. Liposomal doxorubicin. J. Drug Target. 4 (1996) 129-140
3. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Maddin T.D., and Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol. 391 (2005) 71-97
4. Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol. 7 (2007) 72-74
5. Schmid P., Krocker J., Kreienberg R., Klare P., Kittel K., Sommer H., Heinrich G., Steck T., Lichtenegger W., Elling D., and Kummel S. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemother. Pharmacol. 64 (2009) 401-406
6. Cortes J., DiCosimo S., Climent M.A., Cortes-Funes H., Lluch A., Gascon P., Mayordomo J.I., Gil M., Benavides M., Cirera L., Ojeda B., Rodriguez C.A., Trigo J.M., Vazquez J., Reguerio P., Dorada J.F., and Baselga J. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin. Cancer Res. 15 (2009) 307-314
7. Stavridi F., and Palmier C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev. Anticancer Ther. 8 (2008) 1859-1869
8. Swenson C.E., Bolcsak L.E., Batist G., Troy Jr. T.H., Tkaczuk K.H., Boxenbaum H., Welles L., Chow S.-C., Bhamra R., and Chaikin P. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 14 (2003) 239-346
9. Mross K., Niemann B., Massing U., Drevs J., Unger C., Bhamra R., and Swenson C.E. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother. Pharmacol. 54 (2004) 514-524
10. Anderson A.B., Ciriacks C.M., Fuller K.M., and Arriaga E.A. Distribution of zeptomole-abundant doxorubicin metabolites in subcellular fractions by capillary electrophoresis with laser-induced fluorescence detection. Anal. Chem. 75 (2003) 8-15
11. Chen Y., Walsh R.J., and Arriaga E.A. Selective determination of the doxorubicin content of individual acidic organelles in impure subcellular fractions. Anal. Chem. 77 (2005) 2281-2287
12. FDA, Guidance for Industry. Bioanalytical method validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, BP, May 2001.